Results 71 to 80 of about 1,837 (187)

Oxypurinol limits myocardial stunning but does not reduce infarct size after reperfusion.

, 1987
To explore the role of oxygen free radicals produced by the xanthine oxidase pathway on infarct size and left ventricular function, the effect of oxypurinol, an active metabolite of allopurinol and a potent noncompetitive inhibitor of xanthine oxidase ...
D W Puett, K R Hande, C U Cates, B H Wilson, G C Friesinger, M B Forman, R Virmani   +6 more
core   +1 more source

Gout and its management

Internal Medicine Journal, Volume 54, Issue 5, Page 716-723, May 2024.
Abstract Gout is a common and treatable chronic disease of monosodium urate crystal deposition. It is experienced as extremely painful episodes of joint inflammation that impact all aspects of the person's life. This Clinical Perspectives article provides an update on gout diagnosis, medications and strategies to improve the quality of gout care.
Nicola Dalbeth, Leanne Te Karu, Lisa K. Stamp   +2 more
wiley   +1 more source

Oxypurinol administration fails to prevent free radical-mediated lipid peroxidation during loaded breathing

, 1999
The purpose of the present study was to determine whether it is possible to alter the development of fatigue and ablate free radical-mediated lipid peroxidation of the diaphragm during loaded breathing by administering oxypurinol, a xanthine oxidase ...
A. DiMarco, G. Supinski, D. Stofan, D. Nethery, L. Szweda   +4 more
core   +1 more source

How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose

Arthritis Research & Therapy, 2018
Objective Allopurinol dosing has frequently been limited based on creatinine clearance (CrCL), resulting in failure to achieve target serum urate (SU).
Lisa K. Stamp, Peter T. Chapman, Murray L. Barclay, Anne Horne, Christopher Frampton, Paul Tan, Jill Drake, Nicola Dalbeth   +7 more
doaj   +1 more source

Serum metabonomic study to explore the amelioration mechanisms of co‐fermented collagen peptide‐jackfruit juice on the immunosuppressed mice

eFood, Volume 5, Issue 1, February 2024.
Metabolomics approach developed herein provides novel insight onto the metabolic disturbances associated with immunosuppression, and helped to further understand the mechanism of FPJ and provide a basis for further research. Abstract The main purpose of this study was to investigate the improvement effect and serum metabolomic analysis of co‐fermented ...
Tingting Ma, Ming Cheng, Xin Wen, Kexue Zhu, Xin Zhang, Chao Zhao, Hesham R. El‐Seedi, Xiangdong Lin, Yongcheng Li, Lulu Zhu, Jun Cao, Chuan Li   +11 more
wiley   +1 more source

A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol [PDF]

J Pers Med
Cohort studies have identified several genetic determinants that could predict the clinical response to allopurinol. However, they have not been commonly used for genome-wide investigations to identify genetic determinants on allopurinol metabolism and ...
Meloche M, Pilon M, Provost S, Leclair G, Oussaïd E, St-Jean I, Jutras M, Gaulin M, Lemieux Perreault L, Valois D, Mongrain I, Busseuil D, Rouleau J, Tardif J, Dubé M, de Denus S.   +15 more
europepmc   +2 more sources

Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions

, 2015
Allopurinol, a first-line drug for treating gout and hyperuricemia, is one of the leading causes of severe cutaneous adverse reactions (SCARs). To investigate the molecular mechanism of allopurinol-induced SCAR, we enrolled 21 patients (13 Stevens ...
Chu, Mu-Tzu, Hung, Shuen-Iu, Pan, Ren-You, Chang, Jen-Yun, Chin, See-Wen, Huang, Yu-Lin, Chung, Wen-Hung, Wang, Wei-Chi   +7 more
core   +1 more source

Hámörkun á UPLC-MS/MS magngreiningaraðferð fyrir 2,8-díhýdroxýadenín og oxypurinol

, 2016
Background: Adenine phosporibosyltransferase (APRT) deficiency is a metabolic disorder which is the cause of adenine oxidation to 2,8-dihydroxyadenine (DHA) instead of normal conversion to AMP.
Ómar Rafn Stefánsson 1985-
core  

Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.

, 2008
OBJECTIVES: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical ...
Brown, Joanne, BSc, Fisher, Charles, MD, Mann, Douglas L, MD, Givertz, Michael M, MD, Hare, Joshua M, MD, Liu, Peter, MD, Freudenberger, Ronald S, MD, Mangal, Brian, MSc, Colucci, Wilson S, MD, Schwarz, Richard P, PhD   +9 more
core  

The xanthine oxidase inhibitor oxypurinol does not limit infarct size in a canine model of 40 minutes of ischemia with reperfusion

, 1988
Free radicals such as superoxide (O2−) produced by xanthine oxidase might cause cell death during reperfusion after myocardial ischemia. The effect of the xanthine oxidase inhibitor allopurinol on infarct size in ischemiareperfusion models has been ...
Jennings, Robert B, Murry, Charles E, Reimer, Keith A, Richard, Vincent J, Kinsman, James M   +4 more
core   +1 more source